The Advances of Cold Plasma in the Biomedicines

A special issue of Plasma (ISSN 2571-6182).

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 2194

Special Issue Editor


E-Mail Website
Guest Editor
Department of Oral Anatomy, School of Dentistry, Pusan National University, Yangsan 50612, Korea
Interests: tissue regeneration; cancer treatment; detal treatment; plasma medical device
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Plasma used in industrial fields requires a vacuum state and has a characteristic of generating high heat. When the temperature of the plasma is less than 250 degrees Celsius, it is called low-temperature plasma. In order to be treated on human tissues, the temperature of the plasma must be less than 40 degrees Celsius. In that respect, it has recently been referred to as Cold Plasma. The definition of plasma used in the biomedical field seems to be more appropriate for cold plasma than for low-temperature atmospheric pressure plasma or non-thermal plasma. Therefore, in this Special Issue, I look forward to the unified usage of the term “cold plasma”.

Plasma medicine, which started when cold plasma was applied to bacteria and cells, has made much progress for nearly 20 years. The scope of plasma research is expanding from just killing pathogens and cancer cells to tissue regeneration and selective cancer cell death. Among the numerous constituents of plasma, studies on which ones have medical functions and the mechanisms by which plasma-induced biomedical phenomena depend on are being actively conducted. Plasma medical devices are being developed based on these studies, and it is expected that various plasma medical devices will be introduced to the medical market in the near future.

In the current research climate, this Special Issue, as the joint special issue (https://www.mdpi.com/journal/biomedicines/special_issues/Plasma_Biomedicines) with our sister journal /Biomedicines/ (ISSN 2227-9059), calls for all advanced plasma medicine research including various life phenomena induced by plasma. Experimental as well as review papers consistent with this research topic are welcome.

Prof. Dr. Gyoocheon Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Plasma is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cold plasma (non-thermal plasma, low temperature plasma)
  • pathogen sterilization
  • regeneration
  • disease treatment
  • medical device
  • biomaterial

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1616 KiB  
Communication
Extracellular Heat Shock Protein 27 Is Released by Plasma-Treated Ovarian Cancer Cells and Affects THP-1 Monocyte Activity
by Debora Singer, Can Pascal Wulff, Matthias B. Stope and Sander Bekeschus
Plasma 2022, 5(4), 569-578; https://doi.org/10.3390/plasma5040040 - 06 Dec 2022
Cited by 1 | Viewed by 1555
Abstract
Heat shock protein 27 (Hsp27) is a cytoprotective molecule and is inducible via oxidative stress. Anti-cancer therapies, such as the recently investigated gas plasma, subject tumor cells to a plethora of reactive oxygen species (ROS). In ovarian tumor microenvironments (TME), immune cells such [...] Read more.
Heat shock protein 27 (Hsp27) is a cytoprotective molecule and is inducible via oxidative stress. Anti-cancer therapies, such as the recently investigated gas plasma, subject tumor cells to a plethora of reactive oxygen species (ROS). In ovarian tumor microenvironments (TME), immune cells such as monocytes and macrophages can be found in large numbers and are often associated with cancer progression. Therefore, we quantified extracellular Hsp27 of OVCAR-3 and SK-OV-3 cells after gas plasma exposure in vitro. We found Hsp27 to be significantly increased. Following this, we investigated the effects of Hsp27 on THP-1 monocytes. Live cell imaging of Hsp27-treated THP-1 cells showed decelerated cell numbers and a reduction in cell cluster sizes. In addition, reduced metabolic activity and proliferation were identified using flow cytometry. Mitochondrial ROS production decreased. Using multicolor flow cytometry, the expression profile of eight out of twelve investigated cell surface markers was significantly modulated in Hsp27-treated THP-1 cells. A significantly decreased release of IL18 accommodated this. Taken together, our results suggest an immunomodulatory effect of Hsp27 on THP-1 monocytes. These data call for further investigations on Hsp27’s impact on the interplay of ovarian cancer cells and monocytes/macrophages under oxidative stress conditions. Full article
(This article belongs to the Special Issue The Advances of Cold Plasma in the Biomedicines)
Show Figures

Figure 1

Back to TopTop